Entrepreneurship & Innovation for Leber's Congenital Amaurosis (E&ILCA).

Entrepreneurship & Innovation for Leber’s Congenital Amaurosis (E&ILCA) started in January 2016. Led by the strong desire to reach every rare disease patient affected by Leber’s Congenital Amaurosis, E&ILCA takes responsibility to provide access to information about treatments for patients, regardless of their location in the world. E&ILCA is a for-purpose enterprise focused on improving family life for those suffering from LCA. E&ILCA's main focus is cutting-edge technologies, advancing translational sciences & global liaising for genetically caused blindness. To integrate patient-centric research with scientific expertise, E&ILCA leads in the proactive establishment of communication between global stakeholders. E&ILCA initiates and fosters vast networks of top life-science clusters and most influential groups, including physicians, insurance, patient advocacy organizations, national health institutes, investment associates, governments, and academics. With the use of numerous social media platforms, virtual conferences, local scientific events, national symposia, and international conferences, E&ILCA raises public awareness & educates about the needs of rare disease patients. E&ILCA successfully created and implemented unconventional and innovative ways to engage the general public.